The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 9, Issue 2, 2015, Pages 320-330

  Vigersky, Robert A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Glycemic control; Hypoglycemia; Technology

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE METER; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG DOSE CALCULATOR; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TECHNOLOGY; BLOOD GLUCOSE MONITORING; DIABETES COMPLICATIONS; ECONOMICS; PROCEDURES;

BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; INSULIN INFUSION SYSTEMS;

EID: 84942807161     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814565661     Document Type: Review

References (71)

1. Rosenthal E. Even small medical advances can mean big jumps in bills. New York Times. April 5, 2014. Available at: http://www.nytimes.com/2014/04/06/health/even-small-medicaladvances-can-mean-big-jumps-in-bills.html?-r =0. Accessed September 23, 2014.
2. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 174:678-86, 2014
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Eng J Med. 1993;329:977-986.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med. 2005;353:2643-2653.
5. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46:271-276.
6. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry. J Clin Endo Metab. 2013;98:3411-3419.
7. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes. Diabetes Care. 2013;36:3535-3542.
8. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endo Metab. 2013;98:1845-1859.
9. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;36(suppl 1):S14-S80.
10. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2008:25:501-504.
11. Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2010;87:64-68.
12. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med. 2010;27:666-672.
13. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016-1021.
14. Leiter Al, Yale FJ, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes in glycemic and hypoglycemia management. Can J Diabetes. 2005; 29:186-192.
15. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17:673-680.
16. Brod M, Wolden M, Christensen T, Bushnell DM. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health. 2013;16:1140-1140.
17. Cavanaugh K, Huizinga MM, Wallston KA, et al. Association of numeracy and diabetes control. Ann Int Med. 2008;148: 737-746.
18. Sussman A, Taylor EJ, Patel M, et al. Performance of a glucose meter with a built-in automated bolus calculator versus manual bolus calculation in insulin-using subjects. J Diabetes Sci Technol. 2012;6:330-344.
19. Diabetes In Control. Updated bolus calculators for diabetes management. Issue 721, March 20, 2014. Available at: http://www.diabetesincontrol.com/articles/diabetes-news/16063-updated-bolus-calculators-for-diabetes-management-. Accessed October 2014.
20. Schmidt S, Norgaard K. Bolus calculators. J Diabetes Sci Technol. 2014;8:1035-1041.
21. Garg SK, Bookout TR, McFann KK, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008;10:369-375.
22. Ramotowska A, Golicki D, Dzygalo K, Szypowska A. The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus-A systematic review. Exp Clin Endocrinol Diabetes. 2013;121:248-254.
23. Barnard K, Parkin C, Young A, Ashraf M. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. J Diabetes Sci Technol. 2012;6:144-149.
24. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-Analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-774.
25. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring: comparative effectiveness. Comparative Effectiveness Review 57, AHRQ Publication 12-EHC036-EF. Rockville, MD: Agency for Healthcare Research and Quality; July 2012. Available at: www.effectivehealthcare. ahrq.gov/reports/final.cfm.
26. Fatourechi MM, Kudva YC, Murad MH, Elamin MB, Tabini CC, Montori VM. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-Analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009;94(3):729-740.
27. Pickup J. The evidence base for diabetes technology: appropriate and inappropriate meta-Analysis. J Diabetes Sci Technol. 2013;7:1567-1574.
28. Frias JP, Bode BW, Bailey TS, Kipnes, Brunelle R, Edelman SV. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol. 2011;5:887-893.
29. Walsh J, Roberts R. Pumping Insulin. 5th ed. San Diego, CA: Torrey Pines Press; 2012.
30. Lin MH, Connor CG, Ruedy KJ, et al. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol Ther. 2013;15:929-934.
31. Klingensmith GJ, Miller KM, Beck RW, et al. Racial disparities in insulin pump therapy and hemoglobin A1c among T1D exchange participants. Diabetes. 2012;61(suppl 1):A358.
32. Icks A, Razum O, Rosenbauer J, et al. Lower frequency of insulin pump treatment in children and adolescents of Turkish background with type 1 diabetes: analysis of 21,497 patients in Germany. Diabetes Technol Ther. 2012;14:1105-1109.
33. ScuffiC, Lucarelli F, Valgimigli F. Minimizing the impact of time lag variability on accuracy evaluation of continuous glucose monitoring systems. J Diabetes Sci Technol. 2012;6:1383-1391.
34. Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus J Diabetes Sci Technol. 2012;6:1094-1102.
35. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9:203-210.
36. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378-1383.
37. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34: 795-800.
38. Liebl A, Henrichs HR, Heinemann L, et al. Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol. 2013;7:500-519.
39. Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36:4160-4162.
40. Chico A, Vidal-Rios P, Subira M, Novials. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurement for improving metabolic control. Diabetes Care. 2003;26:1153-1157.
41. Zick R, Petersen B, Richter M, Haug C, SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007;9:483-492.
42. Yoo HJ. RT-CGM as a motivational tool for poorly controlled type 2. Diabetes Res Clin Pract. 2008;82:73-79.
43. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50.
44. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short-And long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32-38.
45. Diabetes Research in Children Network (DirecNet) Study Group, Buckingham B, Beck RW, et al. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007;15:388-393.
46. Danne T, de Valk HW, Kracht T, et al. Reducing glycaemic variability in type 1 diabetes self-management with a continuous glucose monitoring system based on wired enzyme technology. Diabetologia. 2009;52:1496-1503.
47. Diabetes Research in Children Network Study Group, Weinzimer S, Xing D, et al. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes. 2009;10:91-96.
48. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
49. Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D Exchange Clinic Registry. Diabetes Care. 2014;37:2702-2709.
50. Li R, Barker LE, Shrestha S, et al. Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes 2001-2011. Diabetes Care. 2014;37:1620-1635.
51. Ramchandani N, Arya S, Ten S, Bhandari S. Real-life utilization of real-time continuous glucose monitoring: the complete picture. J Diabetes Sci Technol. 2011;5:860-870.
52. Bergenstal R, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-Augmented insulin-pump therapy in type 1 diabetes. N Eng J Med. 2010;363:311-320.
53. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia N Eng J Med. 2013;369:224-232.
54. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-Augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes. JAMA. 2013;310:1240-1247.
55. Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37:1885-1991.
56. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
57. Beck RW, Raghinaru D, Wadwa RP, et al. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care. 2014;37:1224-1229.
58. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Eng J Med. 2013;368:824-833.
59. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care. 2014;37:1931-1937.
60. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Eng J Med. 2014;371:313-325.
61. Braithwaite RS, Meltzer DO, King JT Jr., Leslie D, Roberts MS. What does the value of modern medicine say about the 50,000 per quality-Adjusted life-year decision rule? Med Care. 2008;46:349-356.
62. Baltussen RM, Adam T, Tan Torres T, et al. Generalized Cost-Effectiveness Analysis: A Guide. Global Programme on Evidence for Health Policy. Geneva, Switzerland: World Health Organization; 2002.
63. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endo Pract. 2014;20:463-489.
64. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-Augmented pump therapy in adults with type 1 diabetes in the United States. Value Health. 2012;15:632-638.
65. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-Augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Techno Ther. 2010;12:249-255.
66. David G, Shafiroff J, Saulnier A, Gunnarsson C. Multiple daily injection therapy (MDI) versus durable insulin pump therapy in type II diabetics: a breakeven analysis. Value Health. 2012;15:A65.
67. Huang ES, O'Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33:1269-1274.
68. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011;9:13.
69. Ly TT, Brnabic AJM, Eggleston A, et al. Cost-effectiveness of sensor-Augmented insulin pump and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health. 2014;17: 561-569.
70. Graham C, Bowman L, Lewis J, Murphy B. Decision analytic model: cost implications of RT-CGM use in insulin requiring patients with hypoglycemic unawareness. Paper presented at: 7th International Conference on Advanced Technologies and Treatments for Diabetes; February 2014; Vienna, Austria.
71. Fonda SJ, Graham C, Samyshkin Y, Munakata J, Powers J, Price D, Vigersky RA. Cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes (T2DM). Submitted for publication.